Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Aims to boost speed & precision in patient care
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Pharma giant targets new standards of care
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
